Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL197558 | 0.95 | — | — | |
| Acetic Acid SCHEMBL285307 | 0.95 | — | — | |
| Acetic Acid SCHEMBL7645779 | 0.95 | FFAR3 (0.78) | — | |
| Acetic Acid SCHEMBL28234994 | 0.90 | — | — | |
| Acetic Acid SCHEMBL28265503 | 0.90 | — | — | |
| Acetic Acid SCHEMBL28203236 | 0.90 | — | — | |
| Acetic Acid SCHEMBL2848522 | 0.89 | FFAR3 (0.88) | — | |
| Acetic Acid SCHEMBL20537337 | 0.89 | FFAR3 (0.88) | — | |
| Acetic Acid SCHEMBL462200 | 0.89 | FFAR3 (0.88) | — | |
| Acetic Acid SCHEMBL21197465 | 0.89 | FFAR3 (0.88) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6924109-B2 | High-throughput transcriptome and functional validation analysis | AGY THERAPEUTICS, INC. (US) | 2005-08-02 | — | — | US | disclosed |
| US-20050053936-A1 | High-throughput transcriptome and functional validation analysis | AGY THERAPEUTICS, INC. | 2005-03-10 | — | — | US | disclosed |
| US-6841351-B2 | High-throughput transcriptome and functional validation analysis | AGY THERAPEUTICS, INC. (US) | 2005-01-11 | — | — | US | disclosed |
| EP-1444362-A2 | HIGH-THROUGHPUT TRANSCRIPTOME AND FUNCTIONAL VALIDATION ANALYSIS | Agy Therapeutics, Inc. (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20030082570-A1 | High-throughput transcriptome and functional validation analysis | AGY THERAPEUTICS, INC. | 2003-05-01 | — | — | US | disclosed |
| WO-2003033673-A2 | HIGH-THROUGHPUT TRANSCRIPTOME AND FUNCTIONAL VALIDATION ANALYSIS | AGY THERAPEUTICS, INC. (US) | 2003-04-24 | — | — | WO | disclosed |
| US-20030027168-A1 | Generation of preferential nucleotide sequence; obtain complimentary nucleotide sequences, incubate with primers, amplify, recover nucleotide sequences | AGY THERAPEUTICS, INC. (US) | 2003-02-06 | — | — | US | disclosed |